NHERF1 and neoplasm: The tumourigenic mutations of NHERF1 partially or completely disrupt the binding of SYK or merlin, both of which are tumour suppressors [19,20,42,43], suggesting that NHERF1 converges in a pathway mediated by the two tumour suppressors.